Drug	Schedule
2,5-Dimethoxyamphetamine (7396). Amphetamine (1100)	

The company plans to manufacture Phenylacetone to be used in the manufacture of Amphetamine for distribution to its customers. The bulk 2,5-Dimethoxyamphetamine will be used for conversion into non-controlled substances.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than January 30, 2007.

Dated: November 21, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6–20347 Filed 11–30–06; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. § 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on October 3, 2006, JFC Technologies LLC., 100 West Main Street, P.O. Box 669, Bound Brook, NJ 08805, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Meperidine intermediate-

B (9233), a basic class of controlled substance listed in schedule II.

The company plans to import the basic class of controlled substance for the production of controlled substances for distribution to its customers.

Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, VA 22301; and must be filed no later than January 2, 2007.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substance listed in schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. § 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied

Dated: November 21, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6–20346 Filed 11–30–06; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 28, 2006, JFC Technologies, LLC., 100 W. Main Street, Bound Brook, New Jersey 08805, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Diphenoxylate (9170) Hydrocodone (9193)	=

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than January 30, 2007.

Dated: November 21, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6–20338 Filed 11–30–06; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on September 20, 2006, Johnson Matthey, Inc., Pharmaceutical Materials, 2003 Nolte Drive, West Deptford, NJ 08066–1742, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of

the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Phenylacetone (8501)	II

The company plans to import the listed controlled substances as raw materials for use in the manufacture of bulk controlled substances for distribution to its customers.

Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, VA 22301; and must be filed no later than January 2, 2007.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substance listed in schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 USC 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.

Dated: November 21, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6–20333 Filed 11–30–06; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 28, 2006, and October 25, 2006, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Methadone (9250)	II
Methadone Intermediate (9254)	II

The company plans to use the Methadone Intermediate to produce the Methadone HCL for sale to its customers who are final dosage manufacturers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than January 30, 2007.

Dated: November 21, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6–20343 Filed 11–30–06; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 7, 2006, Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, NJ 08066, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Tetrahydrocannabinols (7370) I Dihydromorphine (9145) I Difenoxin (9168) I Propiram (9649) I Amphetamine (1100) II Methamphetamine (1105) II Methylphenidate (1724) II Codeine (9050) II Dihydrocodeine (9120) II Dihydrocodeine (9120) II Hydromorphone (9150) II Hydromorphone (9150) II Hydrocodone (9193) II Hydrocodone (9193) II Hydrocodone (9193) II Mopphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanii (9737) II Sufentanii (9740) II Fentanyl (9801) II	Drug	Schedule
Difenoxin (9168)	Tetrahydrocannabinols (7370)	I
Propiram (9649) I Amphetamine (1100) II II Methamphetamine (1105) II Methamphetamine (1105) II Methylphenidate (1724) II Codeine (9050) II Dihydrocodeine (9120) II Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanii (9737) II Sufentanii (9740) II		1
Propiram (9649) I Amphetamine (1100) II II Methamphetamine (1105) II Methamphetamine (1105) II Methylphenidate (1724) II Codeine (9050) II Dihydrocodeine (9120) II Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanii (9737) II Sufentanii (9740) II	Difenoxin (9168)	1
Amphetamine (1100) II Methamphetamine (1105) II Methylphenidate (1724) II Codeine (9050) II Dihydrocodeine (9120) II Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanil (9737) II Sufentanil (9740) II		1
Methylphenidate (1724) II Codeine (9050) II Dihydrocodeine (9120) II Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanil (9737) II Sufentanil (9740) II		II
Codeine (9050) II Dihydrocodeine (9120) II Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanil (9737) II Sufentanil (9740) II	Methamphetamine (1105)	II
Codeine (9050) II Dihydrocodeine (9120) II Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanil (9737) II Sufentanil (9740) II	Methylphenidate (1724)	II
Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanii (9737) II Sufentanii (9740) II		II
Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanii (9737) II Sufentanii (9740) II	Dihydrocodeine (9120)	II
Hydromorphone (9150)		II
Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanil (9737) II Sufentanil (9740) II		II
Meperidine (9230) II Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanil (9737) II Sufentanil (9740) II	Hydrocodone (9193)	II
Morphine (9300) II Thebaine (9333) II Oxymorphone (9652) II Alfentanil (9737) II Sufentanil (9740) II	Meperidine (9230)	II
Thebaine (9333) II Oxymorphone (9652) II Alfentanil (9737) II Sufentanil (9740) II	Morphine (9300)	II
Oxymorphone (9652) II Alfentanil (9737) II Sufentanil (9740) II		II
Alfentanil (9737) II Sufentanil (9740) II		II
Sufentanil (9740) II	Alfentanil (9737)	Ш
Fentanyl (9801) II		Ш
	Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for sale to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, VA 22301; and must be filed no later than January 30, 2007.

Dated: November 21, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6–20344 Filed 11–30–06; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR),